Ranbaxy gets nod from US FDA to market Doxycycline tablets

Mumbai, June 2 (UNI) Ranbaxy Laboratories has received approval from the US Food and Drug Administration (FDA) to manufacture and market Doxycycline tablets - 50mg, 75mg and 100mg in the US market.

Informing the BSE, the company said the office of generic drugs, FDA has determined the company formulations to be bioequivalent and have the same therapeutic effect as that of the branded drug Adoxa, marketed by Bioglan Pharmaceutical Co.

Annualised sales for Adoxa were US dollar 57.2 million of Doxycycline market, which achieved sales of USD 62.70 million.

Doxycycline is indicated for a variety of infections when caused by susceptible strains or micro-organisms, including respiratory tract and urinary tract infections, skin and skin structure infections and severe acne as adjunctive therapy.

UNI SN GK AG1623